Table 1.
ADR identification task | Seriousness assessment task | |||
---|---|---|---|---|
Development dataset (n = 10,403) |
External validation dataset (n = 1230) |
Development dataset (n = 4786) |
External validation dataset (n = 404) |
|
Patient age, years | ||||
Median (IQR) | 51 (37–62) | 51 (39–63) | 41 (30–58) | 39 (31–56) |
Patient sex, n (%) | ||||
Female | 8792 (84.5) | 1056 (85.9) | 3732 (78.0) | 313 (77.5) |
Encoded PTs per report, n | ||||
Median (IQR) | 4 (2–6) | 5 (3–7) | 3 (1–5) | 3 (2–6) |
Reported drugs per report, n | ||||
Median (IQR) | 1 (1–1) | 1 (1–1) | 1 (1–1) | 1 (1–1) |
Reports about vaccines, n (%) | ||||
Yes | 275 (2.6) | 13 (1.1) | 275 (5.7) | 13 (3.2) |
Reports considered serious, n (%) | ||||
Yes | 2454 (23.6) | 136 (11.1) | 1128 (23.6) | 84 (20.8) |
ADRs adverse drug reactions, IQR interquartile range, PTs Preferred Terms